Bioxytran Interview at the Emerging Growth Conference
January 24, 2023 14:10 ET
|
BIOXYTRAN, INC.
- Wednesday, January 25, 2023 10:50 am –11:20am EST - Discussion of the Biotech Showcase Conference BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million
January 10, 2023 08:35 ET
|
Palisade Bio, Inc.
Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage...
Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
December 30, 2022 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
December 30, 2022 08:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Bioxytran Interview at the Emerging Growth Conference
December 12, 2022 09:45 ET
|
BIOXYTRAN, INC.
Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
December 08, 2022 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
December 07, 2022 08:35 ET
|
Palisade Bio, Inc.
Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
December 01, 2022 14:44 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
November 22, 2022 08:35 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic...
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
November 18, 2022 08:05 ET
|
Palisade Bio, Inc.
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries Well-versed with LB1148 -...